share_log

Virpax Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Mitchell P. Kopin(4.99%),Daniel B. Asher(4.99%), etc.

SEC announcement ·  May 24 04:15
Summary by Futu AI
On May 14, 2024, Virpax Pharmaceuticals, Inc. filed a Schedule 13G with the SEC, indicating a significant acquisition of shares by Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC. The filing, made under Rule 13d-1(c), shows that each of the reporting persons has shared voting and dispositive power over 110,727 shares of common stock, representing approximately 4.99% of the company's class of securities. This ownership level is just below the 5% threshold that typically requires additional disclosure and potential regulatory scrutiny. The shares in question include those issuable upon the exercise of two warrants, with blocker provisions preventing ownership exceeding 4.99% of the common stock. The filing also includes a Joint Filing Agreement between the parties involved, stating their collective responsibility for the accuracy and timeliness of the information provided. The transaction was part of a Securities Purchase Agreement with Virpax Pharmaceuticals, as disclosed in a Form 8-K filed on May 17, 2024.
On May 14, 2024, Virpax Pharmaceuticals, Inc. filed a Schedule 13G with the SEC, indicating a significant acquisition of shares by Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC. The filing, made under Rule 13d-1(c), shows that each of the reporting persons has shared voting and dispositive power over 110,727 shares of common stock, representing approximately 4.99% of the company's class of securities. This ownership level is just below the 5% threshold that typically requires additional disclosure and potential regulatory scrutiny. The shares in question include those issuable upon the exercise of two warrants, with blocker provisions preventing ownership exceeding 4.99% of the common stock. The filing also includes a Joint Filing Agreement between the parties involved, stating their collective responsibility for the accuracy and timeliness of the information provided. The transaction was part of a Securities Purchase Agreement with Virpax Pharmaceuticals, as disclosed in a Form 8-K filed on May 17, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.